This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leeming, D. J. Articles by Tankó, L. B. Search for Related Content PubMed PubMed Citation Articles by Leeming, D. J. Articles by Tankó, L. B. Related Collections Early Detection Early Detection: Biomarkers: Discovery, Methodology, Validation

The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients

¹ Nordic Bioscience Diagnostics A/S, Herlev, Denmark; ² Cancer Institute Hospital, Tokyo, Japan; and ³ Center for Clinical and Basic Research, Ballerup, Denmark

Requests for reprints: Diana J. Leeming, Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730 Herlev, Denmark. Phone: 45-4452-5216; Fax: 45-4454-8888. E-mail: djl{at}nordicbioscience.com

The present study was sought to assess the relative use of eight biomarkers for the detection of bone metastases in cancer forms frequently spreading to the skeleton. Participants were 161 patients with either breast, prostate, or lung cancer. The presence and extent of bone metastases was assessed by imaging techniques (computer tomography and/or magnetic resonance imaging) and Technetium-99m scintigraphy. Serum or urinary level of the bone resorption markers (CTX, ßßCTX, NTX, and ICTP), formation marker (BSAP), and osteoclastogenesis markers (osteoprotegerin, RANKL, and TRAP5b) was measured by commercially available immunoassays. When assessed on a group basis, all biomarkers, except for osteoprotegerin and RANKL, were significantly elevated in patients compared with those without bone metastases (P < 0.05). Biomarkers had greater diagnostic value in breast and prostate cancer patients, yet CTX, NTx, and ICTP were able to discriminate lung cancer patients with or without bone metastases (P < 0.05). Strong linear associations were seen between the extent of skeletal infiltration and levels of the different biomarkers, except for osteoprotegerin and RANKL. Furthermore, all biomarkers (except for osteoprotegerin and RANKL) were indicative at the early stage of skeletal involvement (one to five metastases). When expressing sensitivity as the percentage increase in biomarker level relative to patients without bone metastases, CTX showed the largest relative increases at each stage of the metastatic disease. These results suggest that closer monitoring of cancer patients with serial measures of biomarkers might facilitate the timely diagnosis of skeletal metastases. (Cancer Epidemiol Biomarkers Prev 2006;15(1)32–8)

This article has been cited by other articles:

				A. Claudon, P. Vergnaud, C. Valverde, A. Mayr, U. Klause, and P. Garnero New Automated Multiplex Assay for Bone Turnover Markers in Osteoporosis Clin. Chem., September 1, 2008; 54(9): 1554 - 1563. [Abstract] [Full Text] [PDF]

				D. J. Leeming, A. Hegele, I. Byrjalsen, R. Hofmann, P. Qvist, M. A. Karsdal, A. J. Schrader, R. Wagner, and P. Olbert Biochemical Markers for Monitoring Response to Therapy: Evidence for Higher Bone Specificity by a Novel Marker Compared with Routine Markers Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1269 - 1276. [Abstract] [Full Text] [PDF]

				D. J. Leeming, G. Delling, M. Koizumi, K. Henriksen, M. A. Karsdal, B. Li, P. Qvist, L. B. Tanko, and I. Byrjalsen Alpha CTX as a Biomarker of Skeletal Invasion of Breast Cancer: Immunolocalization and the Load Dependency of Urinary Excretion. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1392 - 1395. [Abstract] [Full Text] [PDF]